Medifast (MED) Director Daniel R. Chard Sells 19,089 Shares

What Happened

• Daniel R. Chard, a director of Medifast, sold a total of 19,089 shares in two open‑market sales. On 2026-09-28 he sold 9,545 shares at a weighted‑average price of $11.98 for proceeds of $114,338; on 2026-09-29 he sold 9,544 shares at a weighted‑average price of $11.73 for proceeds of $111,951. Combined proceeds were about $226,289. These were sales (not purchases), which are often routine dispositions by insiders.

Key Details

• Transaction dates and prices:
  • 2026-09-28: 9,545 shares, weighted‑average $11.98 (reported range $11.900–$12.125) [F1]
  • 2026-09-29: 9,544 shares, weighted‑average $11.73 (reported range $11.670–$11.810) [F3]
• Total shares sold: 19,089; total proceeds ≈ $226,289.
• Ownership of shares sold:
  • Some shares sold were owned by The Dan and Allyson Family Irrevocable Trust (Chard is Settlor and Investment Trustee) [F2].
  • Some shares were held in a joint account held by Chard and his spouse [F4].
• Filing timeliness: Report filed 2026-09-30 for trades on 2026-09-28 and 2026-09-29; filing appears timely under Form 4 rules.
• No 10b5-1 plan, tax withholding, or option exercise was disclosed in the provided filing.

Context

• These transactions were outright sales (Form 4 code S). Sales by directors can be routine portfolio management or estate/tax planning and do not by themselves indicate company prospects; purchases are typically viewed as a stronger bullish signal. The filing’s footnotes provide weighted‑average prices and ownership details and offer to disclose per‑trade prices on request.